Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).
Vitt describes it as "wonderful data" that came as a "positive surprise."
Contact Details
Proactive United States
Proactive United States
+1 347-449-0879
